<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE paragraph PUBLIC "-//IFRS//DTD DITA Paragraph//EN" "../../../DocTypes/com.ifrs.doctype/dtd/paragraph.dtd"><paragraph id="IFRS03_IE90" principles="no"><paranum class="- topic/title paragraph/paranum "/><titlealts><navtitle>IE90</navtitle></titlealts><prolog><data name="standard_number" value="IFRS&#xa0;3"/><data name="paranum" value="IE90"/></prolog><body><p id="IFRS03_IE90_P0001">Assume the same facts as in Scenario 1 except that the acquired set of activities       and assets also includes another in-process research and development project       that is developing a compound to treat Alzheimer&#x2019;s disease and is in its final       testing phase (Project 2). Project 2 includes the historical know-how, formula       protocols, designs, and procedures expected to be needed to complete the final       phase of testing. The fair value associated with Project 2 is similar to the fair       value associated with Project 1. No employees, other assets, processes or other       activities are transferred.</p></body></paragraph>